NCT00297570Unknown3 期
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
适应症
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 90
- 试验地点
- 2
研究概览
简要总结
The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy. The aim is to explore a possible benefit in the addition of peg-interferon (Peg-IFN) to imatinib, in terms of the rate of achievement, molecular remission, and response duration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ph+ CML patients in complete cytogenetic response (CCR) after more than 1 year of imatinib therapy.
排除标准
- •Patients in imatinib study
- •Patients with a history of intolerability to interferon.
- •Patients with less than CCR or less than one year of imatinib therapy.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid LeukemiaHealth Care QualityHealth Care EvaluationNCT01227356Uppsala University112
终止
2 期
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid LeukemiaChronic Myeloid LeukemiaNCT00573378University of Michigan Rogel Cancer Center12
已完成
2 期
Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib TherapyChronic Myeloid LeukemiaNCT00858806Università degli Studi di Brescia78
已完成
2 期
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic PhaseChronic Phase of Chronic Myeloid LeukemiaNCT01872442Poitiers University Hospital
已完成
不适用
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in JordanChronic Myeloid Leukemia, Chronic PhaseNCT02977312Hikma Pharmaceuticals LLC91